A new study has found that the COVID-19 pandemic contributed to significant disruptions in breast, colorectal, and cervical cancer screenings at federally qualified health systems spanning 15 states across the United States. The postponed screenings have created...
In a U.S. and Swiss study, nearly all patients with cancer developed an immune response to COVID-19 mRNA vaccines 3 to 4 weeks after receiving their second dose. However, a small group of the patients exhibited no response, raising questions about how their protection...
6/18/2021 ~ The ASCO Post ~ By Matthew Stenger All-Cause Mortality in COVID-19–Positive and COVID-19–Negative Patients With Cancer In a large cohort study reported by Sharafeldin et al in the Journal of Clinical Oncology, researchers from the National COVID Cohort...
https://ascopost.com/news/april-2021/recent-studies-explore-efficacy-of-covid-19-vaccination-in-patients-with-leukemia-and-myeloma/?utm_source=TAP%2DEN%2D041921%2DTrending%5FLeukemia&utm_medium=email&utm_term=68712af64a8c3dc56f28c8c568893ce1 Originally published by: ...